Stocksigma LogoStocksigma Logo

Suven Life Sciences to Present Seven CNS Pipeline Posters at Neuroscience 2026

Suven Life Sciences announced it will present seven scientific posters showcasing its CNS drug discovery and development pipeline at Neuroscience 2026 in

Suven Life Sciences to Present Seven CNS Pipeline Posters at Neuroscience 2026

Suven Life Sciences Ltd · Press Release · 12 Nov 2026, 5:14 pm

Suven Life Sciences to Present Seven CNS Pipeline Posters at Neuroscience 2026 Suven Life Sciences announced it will present seven scientific posters showcasing its CNS drug discovery and development pipeline at Neuroscience 2026 in Washington, DC, scheduled for 14th–18th Nov'26. Presentations highlight key clinical and preclinical assets targeting Alzheimer’s disease, narcolepsy, depression, and schizophrenia. Key pipeline updates include Phase-3 candidates Masupirdine (SUVN-502) and Samelisant (SUVN-G3031), Phase-2b data for Ropanicant (SUVN-911) with Phase-3 planning underway, and First-in-Human Phase-1 results for Tenaclidine (SUVN-I6107). Suven holds full intellectual property rights globally across its five clinical-stage assets and seven research projects.

Original exchange filing (PDF)

More announcements from Suven Life Sciences Ltd

All Suven Life Sciences Ltd announcements